EIF2AK3 and prion disease: In a recently published study by Moreno and colleagues [1], oral treatment of a newly characterized and specific inhibitor of the endoplasmic reticulum-localized kinase PERK (protein kinase RNA-like endoplasmic reticulum kinase), termed GSK2606414 [2], was demonstrated to rescue clinical symptoms as well as brain pathology in a mouse model of prion disease.